
Sausage Recall in 3 States As Listeria Warning Issued
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A Louisiana-based meat processor is recalling around 100 pounds of sausage products because of potential listeria contamination.
Bourgeois Smokehouse, located in Thibodaux, Louisiana, announced the voluntary recall of its ready-to-eat smoked andouille sausage on Tuesday.
The affected items were shipped to Rouses Market retail locations in Alabama, Louisiana and Mississippi.
Newsweek has contacted Bourgeois Smokehouse via email for comment.
Why It Matters
The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) warns that consumption of food contaminated with listeria can cause listeriosis, an infection that can be particularly serious for certain groups.
Listeriosis can cause fever, muscle aches, headaches, stiff neck, confusion, loss of balance and convulsions, diarrhea and other gastrointestinal symptoms.
In pregnant women, the infection can cause miscarriages, stillbirths, premature delivery or life-threatening infection of the newborn. The infection can also be fatal in older adults and people with weakened immune systems.
A photo of the Bourgeois Smokehouse sausage product that has been recalled.
A photo of the Bourgeois Smokehouse sausage product that has been recalled.
Bourgeois Smokehouse
What To Know
The recall was initiated after a sample of the sausage product tested positive for Listeria monocytogenes during a routine FSIS inspection.
The recalled sausages were produced on May 12, 2025. They do not bear an establishment number or the USDA mark of inspection because they were wrapped and labeled in-store at the time of purchase.
They have been available for purchase at Rouses Market stores in Alabama, Louisiana and Mississippi since May 13.
The FSIS has given the recall a Class I classification, meaning that there is a "reasonable probability that the use of the product will cause serious, adverse health consequences or death."
As of Tuesday, there have been no reports of illness linked to the recalled product.
What People Are Saying
FSIS, said in a January 2024 report on controlling Listeria monocytogenes in ready-to-eat meat and poultry products: "[Ready-to-eat (RTE)] products are of particular concern for contamination with [Listeria monocytogenes (Lm) because they may support the growth of the pathogen during refrigerated storage. In addition, since RTE products are often consumed without further cooking, there is a greater possibility of the occurrence of foodborne illness from these products if they become contaminated."
It added: "Lethality treatments such as cooking meat and poultry products generally eliminate Lm; however, RTE products can be re-contaminated by exposure to the environment after the lethality treatment during peeling, slicing, repackaging, and other processing steps. By controlling sanitation in the post-lethality processing environment or implementing interventions in their products, establishments can ensure that their RTE products do not become contaminated with Lm."
What Happens Next
The FSIS says that anyone experiencing symptoms of listeriosis after consuming these products should seek medical attention. Consumers are advised to check their refrigerators and freezers and discard any products matching the recall details. They can also be returned to the place of purchase. FSIS has encouraged any consumers with questions to contact Bourgeois Smokehouse at 985-447-1604 or bourgeoissmokehouse@comcast.net.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support
National Platform Offers Secure Access to Physician-Led TRT and Hormone Health Consultations from Anywhere in the U.S. VERO BEACH, June 10, 2025 (GLOBE NEWSWIRE) -- PeterMD, a Florida-based men's health telemedicine provider, has updated its official website to spotlight its nationwide services focused on testosterone replacement therapy (TRT), hormone optimization, and performance support. Available in all 50 states, PeterMD offers direct-to-consumer access to licensed providers via a secure digital platform. According to the official website ( PeterMD allows adult men to privately consult with certified TRT specialists, receive personalized treatment plans based on lab results, and manage therapy from the comfort of home. Services are available without insurance requirements, with fast turnaround times and HIPAA-compliant care. 'PeterMD was built to eliminate unnecessary barriers to men's health,' said a company spokesperson. 'We believe in transparent, physician-directed care that gives men control over their wellness without waiting rooms or stigma.' The telemedicine platform includes options for lab testing coordination, treatment supervision, and ongoing patient support. Every consultation is handled by a qualified medical professional trained in men's hormone health. Once a plan is approved, therapies are shipped directly with complete oversight from the PeterMD medical team. The updated site features secure registration, FAQs, and real-time access to specialists. New clients are invited to speak directly with a TRT specialist by calling or texting 772-800-6133. For existing patients, dedicated support is available at 772-444-8669 or via email at support@ PeterMD patient support hours: Monday–Sunday: 7 AM – 7 PM EST (for new inquiries) Monday–Friday: 9 AM – 5 PM EST (for existing patients) About PeterMD PeterMD is a telehealth provider based in Vero Beach, Florida, offering customized men's hormone and wellness solutions across the United States. The platform connects users with medical experts for private, fast, and clinically guided treatment—empowering men to reclaim their energy, focus, and vitality through modern, accessible care. Product and Contact Information Brand: PeterMDWebsite: support@ (New Patients): 772-800-6133Phone (Support): 772-444-8669Mailing Address: 601 21st Street, Suite 300, Vero Beach, FL, United StatesBusiness Hours:New Patients: Monday–Sunday, 7 AM – 7 PM ESTSupport: Monday–Friday, 9 AM – 5 PM EST Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All medical decisions should be made in consultation with a licensed healthcare provider. Availability of telemedicine services may vary by state. PeterMD complies with all applicable healthcare regulations. CONTACT: Email: support@ Phone (New Patients): 772-800-6133 Phone (Support): 772-444-8669Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Toxic 'forever chemical' showing up in European food and wine
A team of researchers has found "alarmingly high" levels of trifluoroacetic acid (TFA), a so-called forever chemical, in dozens of organic and non-organic pastas, baked goods and breakfast cereals from Europe, as well as in wine. "In conventional grain products, the average levels were so high that a health risk to children can no longer be ruled out," said Helmut Burtscher-Schaden, an environmental chemist part of the Brussels-based Pesticide Action Network (PAN) Europe, which describes TFA as a "product of PFAS pesticides and industrial chemicals." Forever chemicals, also known as PFAS, are thousands of long-lasting substances used in household and everyday products since the middle of the 20th century but which have been found to be difficult to remove from the environment and from human bodies. The latest research points to 'widespread contamination from PFAS (per- and poly-fluoroalkyl substances) pesticides," PAN Europe said, warning that TFA tends to build up in water and farmland. The amount of TFA in the food items was found to be three times that recorded in a similar study eight years ago, according to PAN Europe, which in April warned of "dramatic rise" of TFA in wine. In a report covering wines from Austria, Belgium, Croatia, France, Germany, Greece, Hungary, Italy, Luxembourg and Spain, PAN Europe found that while pre-1988 vintages do not contain any such contamination, there has been a "sharp increase" in pesticide and chemical residues in wine bottled since 2010. Such a "steep accumulation" should be "a red flag that calls for decisive action," according to Michael Müller, a professor of pharmaceutical and medicinal chemistry at the University of Freiburg. The European Chemicals Agency has warned that TFA "may cause harm to the unborn child" and "may impair fertility."
Yahoo
3 hours ago
- Yahoo
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@